🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Castle Biosciences celebrates an incredible milestone — surpassing the 200,000th order of the DecisionDx-Melanoma test! In the video, Castle founder, president and CEO Derek Maetzold reflects on this significant milestone and is joined by five courageous melanoma survivors who

Castle will share new data on the TissueCypher Barrett’s Esophagus test via two posters at the Digestive Disease Week® Digestive Disease Week Annual Meeting, being held May 3-6 in San Diego. In addition to the product theater, Castle is collaborating with renowned gastrointestinal (GI)

Castle has signed a definitive agreement to acquire Previse, a gastrointestinal health company with a primary focus on chronic acid reflux-related diseases, including esophageal cancer. The acquisition will complement Castle’s current gastroenterology franchise and adds